Peptide Research Library

Tesamorelin closes out Batch 1 because it is the growth-hormone-axis peptide with the strongest regulatory and trial record — a useful refer

Melanotan II is one of the more widely sold research peptides, and also one where the safety record deserves as much attention as the pharma

Sermorelin is one of the longest-standing growth-hormone-axis peptides, with a clinical history that distinguishes it from the newer secreta

Hexarelin is one of the growth-hormone-releasing peptides, notable for its potency and for cardiac effects reported separately from its GH a

GHRP-2 is one of the classic growth-hormone-releasing peptides, frequently studied and discussed alongside GHRP-6 and the GHRH analogs. Chem

GHRP-6 is the GHRP most associated with a strong appetite effect, which is its most distinctive characteristic relative to the rest of the f

AOD-9604 is widely marketed as a "fat-loss peptide", which makes an honest read of its actual trial record especially important. Chemical id

Kisspeptin is a naturally occurring neuropeptide with a well-defined role in reproductive physiology and a genuine, growing human research l

5-Amino-1MQ is sold and discussed alongside peptides, so it belongs in this library — but it is important to begin with what it is not. Chem

DSIP is marketed largely for sleep, which makes a careful look at its actual evidence base important. Chemical identity & structure. DSIP de

Dihexa is one of the most aggressively marketed nootropic peptides, and the gap between the marketing and the evidence is the most important

Humanin is, like MOTS-c in Batch 1, a mitochondrial-derived peptide — a scientifically interesting class with a research base that is still

SS-31 is one of the more clinically advanced compounds in this library, with a genuine pharmaceutical development program behind it. Chemica

KPV is a very short peptide studied mainly for anti-inflammatory activity, particularly in the gut. Chemical identity & structure. KPV is a

LL-37 is a naturally occurring human peptide with a real and well-studied role in innate immunity — and a more complex, double-edged biology

VIP is a naturally occurring signaling peptide with a wide range of physiological roles and a synthetic counterpart that has been studied cl

Oxytocin closes Batch 2. It is unusual here because it is both a long-approved clinical drug for one use and an active subject of behavioral

IGF-1 LR3 is widely discussed in growth-and-recovery research contexts. It is a modified version of a natural human growth factor, and the m

Follistatin 344 is marketed heavily around muscle growth, so a careful look at what it is and what the evidence actually supports is importa

Cagrilintide is part of the modern weight-management research landscape, usually discussed in combination with semaglutide. Chemical identit

Cerebrolysin is unusual in this library: it is not a single defined peptide but a complex biological preparation, and that distinction is th

Mazdutide is one of the newer dual-agonist incretin compounds, part of the same research wave as tirzepatide and retatrutide. Chemical ident

Survodutide is another GLP-1/glucagon dual agonist, notable for a research focus that extends beyond weight management into liver disease. C

Tesofensine is sold and discussed alongside weight-management peptides, so it belongs in this library — but it is important to be clear abou

Adipotide is marketed as a fat-loss peptide. Its mechanism is genuinely distinctive — and its safety record is the reason this monograph is

P21 is a nootropic-category research peptide whose evidence base is entirely preclinical — the most important fact to establish up front. Ch

FOXO4-DRI is marketed within the "longevity" and senolytic space, which makes a careful, honest read of its actual evidence base essential.

ARA-290 is a research peptide with a specific, well-defined scientific rationale and a genuine clinical-research history. Chemical identity

Pinealon belongs to a family of very short peptides — the "peptide bioregulators" — and the shape of that family's evidence base is the key

Cardiogen is another of the short "peptide bioregulators", marketed in a cardiovascular context. The same evidence caveats that apply to the